Wilson Disease Epidemiology Forecast

DelveInsight’s ‘Wilson’s Disease (WD) – Epidemiology Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Wilson’s disease (WD) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Wilson’s disease (WD): Disease Understanding

Wilson’s disease (WD) Overview

According to the European Association for the study of the Liver (EASL), Wilson’s disease (WD) is an inherited disorder in which defective biliary excretion of copper leads to its accumulation, particularly in the liver and brain.

 

The disease is progressive and, if left untreated, may cause liver (hepatic) disease, central nervous system dysfunction, and death. Early diagnosis and treatment may prevent serious long-term disability and life-threatening complications. The features of this condition include a combination of liver disease and neurological and psychiatric problems. Liver disease is typically the initial feature of WD in affected children and young adults; individuals diagnosed at an older age usually do not have symptoms of liver problems, although they may have very mild liver disease. The signs and symptoms of liver disease include yellowing of the skin or whites of the eyes (jaundice), fatigue, loss of appetite, and abdominal swelling. Nervous system or psychiatric problems are often the initial features in individuals diagnosed in adulthood and commonly occur in young adults with WD. Signs and symptoms of these problems can include clumsiness, tremors, difficulty walking, speech problems, impaired thinking ability, depression, anxiety, and mood swings. A mutation in the ATP7B gene, which codes for copper transportation, causes WD. A person must inherit the gene from both parents to have WD.

 

According to the National Organization of Rare Diseases, WD is a disorder that affects males and females in equal numbers. The disease is found in all races and ethnic groups. Although estimates vary, it is believed that WD occurs in approximately one in 30,000–40,000 people worldwide. Approximately 1 in 90 people may be carriers of the disease gene. Although only about 2,000–3,000 cases have been diagnosed in the United States, other affected individuals may be misdiagnosed with neurological, liver, or psychiatric disorders. According to one estimate, there may be 9,000 people affected by WD in the United States.

 

WD can affect many different systems of the body. Affected people often develop signs and symptoms of chronic liver disease in their teenage years or early twenties. These features may include jaundice; abnormal fluid retention, which can lead to swelling of the legs and/or abdomen; weight loss; nausea and vomiting, and/or fatigue. Unfortunately, some people may not experience any signs until they suddenly develop acute liver failure.

 

Affected people often experience a variety of neurologic (central nervous system-related) signs and symptoms, as well. Neurologic features often develop after the liver has retained a significant amount of copper; however, they have been seen in people with little to no liver damage. These symptoms may include tremors, muscle stiffness, and problems with speech, swallowing, and/or physical coordination. Almost all people with neurologic symptoms have Kayser–Fleisher rings – a rusty brown ring around the cornea of the eye that can best be viewed using an ophthalmologist’s slit lamp.

 

Treatment for WD is life-long and aimed at lowering copper levels to nontoxic levels, and at preventing the progression of the disease, and trying to reverse any signs and symptoms that have appeared because of copper accumulation in the body. Treatment may be divided into three parts: first, treatment of symptomatic patients; second, maintenance therapy after the copper has been reduced in affected tissues; and third, in asymptomatic patients, maintenance therapy may be used from the beginning.

 

The several promising novel therapies, including chelators targeting specific cell types and cell-based and gene therapies, may revolutionize the care for WD patients. However, timely clinical diagnosis remains the main challenge, and many unmet needs exist because of possible clinical deterioration in treated patients.

Wilson’s disease (WD): Epidemiology

The Wilson’s disease (WD) epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Wilson’s disease (WD) epidemiology segmented as the prevalent cases of Wilson’s disease, diagnosed cases of Wilson’s disease, prevalent cases of Wilson’s disease based on clinical manifestation, and prevalent cases of Wilson’s disease based on symptoms. The report includes the prevalent scenario of Wilson’s disease (WD) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise, Wilson’s disease (WD) Epidemiology

The epidemiology segment also provides Wilson’s disease (WD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The total prevalent patient population of Wilson’s disease (WD) in the 7MM countries comprised about 37,000 cases in 2021.
  • As per the estimates, Japan had the highest total prevalent patient population of Wilson’s disease (WD) population in 2021. Among the EU5 countries, Germany had the highest total prevalent patient population of Wilson’s disease (WD) with ~3,000 cases, followed by France in 2021. On the other hand, Spain had the lowest total prevalent patient population of Wilson’s disease (WD), close to 750 cases in 2021.

Scope of the Report

  • Wilson’s disease report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
  • Wilson’s disease epidemiology report and model provide an overview of the risk factors and global trends of Wilson’s disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Wilson’s disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Wilson’s disease.
  • The report provides the segmentation of Wilson’s disease epidemiology by prevalent cases of Wilson’s disease in the 7MM.
  • The report provides the segmentation of Wilson’s disease epidemiology by diagnosed cases of Wilson’s disease in the 7MM.
  • The report provides the segmentation of Wilson’s disease epidemiology by mutation-prevalent cases of Wilson’s disease based on clinical manifestation in the 7MM.
  • The report segments Wilson’s disease epidemiology by prevalent cases of Wilson’s disease based on symptoms in the 7MM.

Report Highlights

  • 11-year Forecast of Wilson’s disease epidemiology
  • 7MM Coverage
  • Prevalent cases of Wilson’s disease
  • Diagnosed cases of Wilson’s disease
  • Prevalent cases of Wilson’s disease based on clinical manifestation
  • Prevalent cases of Wilson’s disease based on symptoms.

KOL Views

We interview KOLs and obtain SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

  • What are the major factors that will drive the change in the patient population in Wilson’s disease during the forecast period (2019–2032)?
  • What are the key findings pertaining to Wilson’s disease epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019–2032)?
  • What would be the total number of patients with Wilson’s disease across the 7MM during the forecast period (2019–2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?
  • At what CAGR is the patient population expected to grow in the 7MM forecast period (2019–2032)?
  • What are the disease risk, burdens, and unmet needs of Wilson’s disease?
  • What are the currently available treatments for Wilson’s disease?

Reasons to buy

Wilson’s disease (WD) Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Wilson’s disease (WD) market
  • Quantify patient populations in the global Wilson’s disease market to improve product design, pricing, and launch plans
  • Understand the magnitude of Wilson’s disease population by its prevalent cases.
  • Understand the magnitude of Wilson’s disease population by its diagnosed cases.
  • Understand the magnitude of Wilson’s disease (WD) population by its prevalent cases based on clinical manifestation.
  • Understand the magnitude of Wilson’s disease (WD) population by its prevalent cases based on symptoms.
  • The Wilson’s disease (WD) epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Wilson’s disease (WD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Wilson’s disease Market Overview at a Glance

3.1. Market Share (%) Distribution of WD in 2019

3.2. Market Share (%) Distribution of WD in 2032

4. Executive Summary of Wilson’s disease

5. Disease Background and Overview

5.1. Introduction

5.2. Causes

5.3. Symptoms

5.4. Clinical Manifestation

5.5. Physiology

5.5.1. Copper Metabolism

5.5.2. Cell Biology

5.6. Pathogenesis

5.7. Diagnosis

5.8. Treatment

5.9. Guidelines for Wilson’s disease

6. Patient Journey

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Prevalent Patient Population of Wilson’s disease

7.3. Epidemiology of Wilson’s disease

7.4. The United States

7.4.1. Prevalent Cases of Wilson’s disease in the United States

7.4.2. Diagnosed Cases of Wilson’s disease in the United States

7.4.3. Prevalent cases of Wilson’s disease based on Clinical Manifestation in the United States

7.4.4. Prevalent cases of Wilson’s disease based on Symptoms in the United States

7.5. EU5

7.5.1. Total Prevalent Cases of Wilson’s disease in EU5

7.5.2. Germany

7.5.2.1. Diagnosed Cases of Wilson’s disease in Germany

7.5.2.2. Prevalent cases of Wilson’s disease based on Clinical Manifestation in Germany

7.5.2.3. Prevalent cases of Wilson’s disease based on Symptoms in Germany

7.5.3. France

7.5.3.1. Diagnosed Cases of Wilson’s disease in France

7.5.3.2. Prevalent cases of Wilson’s disease based on Clinical Manifestation in France

7.5.3.3. Prevalent cases of Wilson’s disease based on Symptoms in France

7.5.4. Italy

7.5.4.1. Diagnosed Cases of Wilson’s disease in Italy

7.5.4.2. Prevalent cases of Wilson’s disease based on Clinical Manifestation in Italy

7.5.4.3. Prevalent cases of Wilson’s disease based on Symptoms in Italy

7.5.5. Spain

7.5.5.1. Diagnosed Cases of Wilson’s disease in Spain

7.5.5.2. Prevalent cases of Wilson’s disease based on Clinical Manifestation in Spain

7.5.5.3. Prevalent cases of Wilson’s disease based on Symptoms in Spain

7.5.6. The United Kingdom

7.5.6.1. Diagnosed Cases of Wilson’s disease in the United Kingdom

7.5.6.2. Prevalent cases of Wilson’s disease based on Clinical Manifestation in the United Kingdom

7.5.6.3. Prevalent cases of Wilson’s disease based on Symptoms in the United Kingdom

7.6. Japan

7.6.1. Prevalent Cases of Wilson’s disease in Japan

7.6.2. Diagnosed Cases of Wilson’s disease in Japan

7.6.3. Prevalent cases of Wilson’s disease based on Clinical Manifestation in Japan

7.6.4. Prevalent cases of Wilson’s disease based on Symptoms in Japan

8. SWOT Analysis

9. Unmet Needs

10. Appendix

10.1. Bibliography

10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Tables

Table 1: Summary of Wilson’s Disease, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Society Guidelines

Table 3: Total Prevalent Patient Population of Wilson’s disease in the 7MM (2019–2032)

Table 4: Prevalent Cases of Wilson’s disease in the United States (2019–2032)

Table 5: Diagnosed Cases of Wilson’s disease in the United States (2019–2032)

Table 6: Prevalent cases of Wilson’s Disease based on Clinical Manifestation in the United States (2019–2032)

Table 7: Prevalent cases of Wilson’s disease based on Symptoms in the United States (2019–2032)

Table 8: Total prevalent Cases of Wilson’s disease in EU5 (2019–2032)

Table 9: Diagnosed Cases of Wilson’s disease in Germany (2019–2032)

Table 10: Prevalent cases of Wilson’s disease based on Clinical Manifestation in Germany (2019–2032)

Table 11: Prevalent cases of Wilson’s disease based on Symptoms in Germany (2019–2032)

Table 12: Diagnosed Cases of Wilson’s disease in France (2019–2032)

Table 13: Prevalent cases of Wilson’s disease based on Clinical Manifestation in France (2019–2032)

Table 14: Prevalent cases of Wilson’s disease based on Symptoms in France (2019–2032)

Table 15: Diagnosed Cases of Wilson’s disease in Italy (2019–2032)

Table 16: Prevalent cases of Wilson’s disease based on Clinical Manifestation in Italy (2019–2032)

Table 17: Prevalent cases of Wilson’s disease based on Symptoms in Italy (2019–2032)

Table 18: Diagnosed Cases of Wilson’s disease in Spain (2019–2032)

Table 19: Prevalent cases of Wilson’s disease based on Clinical Manifestation in Spain (2019–2032)

Table 20: Prevalent cases of Wilson’s disease based on Symptoms in Spain (2019–2032)

Table 21: Diagnosed Cases of Wilson’s disease in the United Kingdom (2019–2032)

Table 22: Prevalent cases of Wilson’s disease based on Clinical Manifestation in the United Kingdom (2019–2032)

Table 23: Prevalent cases of Wilson’s disease based on Symptoms in the United Kingdom (2019–2032)

Table 24: Prevalent Cases of Wilson’s disease in Japan (2019–2032)

Table 25:   Diagnosed Cases of Wilson’s disease in Japan (2019–2032)

Table 26: Prevalent cases of Wilson’s disease based on Clinical Manifestation in Japan (2019–2032)

Table 27: Prevalent cases of Wilson’s disease based on Symptoms in Japan (2019–2032)

List of Figures

Figure 1: Inheritance of an Autosomal Recessive Disorder from Carrier Parents

Figure 2: Symptoms of Wilson’s Disease

Figure 3: Illustration of the proteins and pathways critical for hepatocyte copper metabolism.

Figure 4: Structural model of Wilson’s disease copper-transporting ATPase, ATP7b, illustrating adenosine triphosphate (ATP)-dependent copper transport across the lipid bilayer.

Figure 5: Copper toxicity in the pathogenesis of WD

Figure 6: Diagnostic algorithms for Wilson’s disease based on the Leipzig Score

Figure 7: Total Prevalent Population of Wilson’s disease in 7MM (2019–2032)

Figure 8: Prevalent Cases of Wilson’s disease in the United States (2019–2032)

Figure 9: Diagnosed Cases of Wilson’s disease in the United States (2019–2032)

Figure 10: Prevalent cases of Wilson’s Disease based on Clinical Manifestation in the United States (2019–2032)

Figure 11: Prevalent cases of Wilson’s disease based on Symptoms in the United States (2019–2032)

Figure 12: Total prevalent Cases of Wilson’s disease in EU5 (2019–2032)

Figure 13: Diagnosed Cases of Wilson’s disease in Germany (2019–2032)

Figure 14: Prevalent cases of Wilson’s disease based on Clinical Manifestation in Germany (2019–2032)

Figure 15: Prevalent cases of Wilson’s disease based on Symptoms in Germany (2019–2032)

Figure 16: Diagnosed Cases of Wilson’s disease in France (2019–2032)

Figure 17: Prevalent cases of Wilson’s disease based on Clinical Manifestation in France (2019–2032)

Figure 18: Prevalent cases of Wilson’s disease based on Symptoms in France (2019–2032)

Figure 19: Diagnosed Cases of Wilson’s disease in Italy (2019–2032)

Figure 20: Prevalent cases of Wilson’s disease based on Clinical Manifestation in Italy (2019–2032)

Figure 21: Prevalent cases of Wilson’s disease based on Symptoms in Italy (2019–2032)

Figure 22: Diagnosed Cases of Wilson’s disease in Spain (2019–2032)

Figure 23: Prevalent cases of Wilson’s disease based on Clinical Manifestation in Spain (2019–2032)

Figure 24: Prevalent cases of Wilson’s disease based on Symptoms in Spain (2019–2032)

Figure 25: Diagnosed Cases of Wilson’s disease in the United Kingdom (2019–2032)

Figure 26: Prevalent cases of Wilson’s disease based on Clinical Manifestation in the United Kingdom (2019–2032)

Figure 27: Prevalent cases of Wilson’s disease based on Symptoms in the United Kingdom (2019–2032)

Figure 28: Prevalent Cases of Wilson’s disease in Japan (2019–2032)

Figure 29: Diagnosed Cases of Wilson’s disease in Japan (2019–2032)

Figure 30: Prevalent cases of Wilson’s disease based on Clinical Manifestation in Japan (2019–2032)

Figure 31: Prevalent cases of Wilson’s disease based on Symptoms in Japan (2019–2032)

Forward to Friend

Need A Quote